MP01-11: Large, multi-center, prospective registry of Rezūm water vapor therapy benign prostatic enlargement

Friday, May 13, 2022 7:00 AM to 8:15 AM
Room 228
Voiding Dysfunction/BPH


Authors: Dean Elterman*, Toronto, Canada, Naeem Bhojani, Montreal, Canada, Bilal Chughtai, New York, NY, Kevin C Zorn, Montreal, Canada

Introduction: Rezum convective water vapor ablation is a minimally invasive procedure to treat benign prostatic tissue. Herein, we report the prospective, multi-center results of the largest cohort of prostates treated with Rezum in Canada.

Methods: A prospective registry was established for Rezum therapy in Canada (2019) at two high-volume centers. All patients had baseline medical and BPH history documented along with uroflowmetry (Qmax and PVR), and validated questionnaires (IPSS, IPSS QoL, BPHII, IIEF-15, MSHQ-EjD function and bother).

Results: 229 patients (mean age 67.3 years), including 83 with prostate volumes = 80ml, were treated with Rezum from April 2019 to December 2020. The mean prostate volume was 71.5ml (range 20-160ml) and 55% had a median lobe.  39 patients had prior episode of urinary.  Mean number of injections was 11 (range 4-28). Mean duration of procedure was 4.8 minutes (range 1.5-14). Mean duration of post-procedure catheterization was 9.8 days. \n\nIPSS reduced from a baseline score of 22 by 29% (15.8), 53% (10.3), 59% (9.3) at 1, 3, 12 months respectively. IPSS QoL score improved from a baseline of 4.4 to 2.2 (-50%) at 3 months and 1.5 (-66%) at 12 months. Qmax improves from a baseline of 8.7ml/s up to 13.9ml/s (60%) at 3 months. BPHII improved from a baseline of 7.1 to 3.9 (-45%) at 3 months and 2.8 (-63%) at 12 months. IIEF showed no significant change from 51 at baseline to 52 at 12 months. Similarly, no changes in MSHQ function (9.4 to 9.4 at 12 months) or bother (1.7 to 1.6 at 12 months). No Clavien-Dindo events = Grade III occurred.

Conclusions: Rezum therapy is safe, effective, quick, out-patient procedure for prostate glands over a wide range of volumes.

Source of Funding: Not applicable